Experienced in Esophageal Cancer

Dr. Laith Abushahin

Oncology
3410 Worth Street, Suite 400, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
20 Years of Experience
Experienced in Esophageal Cancer
3410 Worth Street, Suite 400, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laith Abushahin is an Oncologist in Dallas, Texas. Dr. Abushahin has been practicing medicine for over 20 years and is rated as an Experienced provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Pancreatic Ductal Adenocarcinoma.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 2 clinical trials in the study of Esophageal Cancer.

Graduate Institution
University Of Jordan, 2006.0
Residency
Internal Medicine Medical Oncology, University of Arizona College of Medicine GME
Specialties
Oncology
Licenses
Internal Medicine in IA
Fellowships
Medical Oncology, Baylor University Medical Center
Hospital Affiliations
Baylor University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 400, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 2
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine
Enrollment Status: Completed
Publish Date: July 28, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Gemcitabine
Study Phase: Phase 1
View 7 Less Clinical Trials

18 Total Publications

First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
Journal: Future oncology (London, England)
Published: May 17, 2022
Similar Doctors
Ronan J. Kelly
Distinguished in Esophageal Cancer
Dr. Ronan J. Kelly
Internal Medicine | Oncology
Distinguished in Esophageal Cancer
Dr. Ronan J. Kelly
Internal Medicine | Oncology

Texas Oncology, P.A.

3410 Worth Street, Suite 400, 
Dallas, TX 
 (0.1 miles away)
972-449-0540
Experience:
28+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ronan Kelly is an Internal Medicine specialist and an Oncologist in Dallas, Texas. Dr. Kelly has been practicing medicine for over 28 years and is rated as a Distinguished provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Esophageal Cancer, Gastroesophageal Junction Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreaticoduodenectomy, and Tissue Biopsy.

Experienced in Esophageal Cancer
Dr. Vibha T. Thomas
Oncology | Internal Medicine
Experienced in Esophageal Cancer
Dr. Vibha T. Thomas
Oncology | Internal Medicine

Texas Oncology, P.A.

4370 Medical Arts Drive Suite, 
Flower Mound, TX 
 (23.5 miles away)
972-724-1707
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vibha Thomas is an Oncologist and an Internal Medicine provider in Flower Mound, Texas. Dr. Thomas has been practicing medicine for over 20 years and is rated as an Advanced provider by MediFind in the treatment of Esophageal Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Dehydration.

Experienced in Esophageal Cancer
Dr. John W. Adams
Oncology | Hematology Oncology
Experienced in Esophageal Cancer
Dr. John W. Adams
Oncology | Hematology Oncology

Texas Oncology PA

515 W Mayfield Rd, Suite 101, 
Arlington, TX 
 (20.5 miles away)
817-664-4400
Languages Spoken:
English, Dutch, Filipino, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

John Adams is an Oncologist and a Hematologist Oncology provider in Arlington, Texas. Dr. Adams is rated as an Advanced provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Colorectal Cancer, Bone Marrow Aspiration, and Gastrostomy. Dr. Adams is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abushahin's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile